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Urinary tractCatheter-associated urinary tract infection (CAUTI) is the commonest hospital-acquired infection, accounting for
over 100,000 hospital admissions within the USA annually. Biomaterials and processes intended to reduce the
risk of bacterial colonization of the catheters for long-term users have not been successful, mainly because of
the need for long duration of activity in ﬂow conditions. Here we report the results of impregnation of urinary
catheters with a combination of rifampicin, sparﬂoxacin and triclosan. In ﬂow experiments, the antimicrobial
catheters were able to prevent colonization by common uropathogens Proteus mirabilis, Staphylococcus aureus
and Escherichia coli for 7 to 12 weeks in vitro compared with 1–3 days for other, commercially available antimi-
crobial catheters currently used clinically. Resistance developmentwasminimized by careful choice of antimicro-
bial combinations. Drug release proﬁles and distribution in the polymer, and surface analysis were also carried
out and the process had no deleterious effect on the mechanical performance of the catheter or its balloon. The
antimicrobial catheter therefore offers for the ﬁrst time a means of reducing infection and its complications in
long-term urinary catheter users.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Urethral catheters are used to drain urine from the bladder (Fig. 1).
Bladder catheterization is commonly required, either for short-term
bladder drainage or for long-termmanagement of bladder dysfunction,
and at least 25% of hospital patients will have a bladder catheter placed
at somepoint in their stay. Short-term catheters are used for the tempo-
rary relief of reversible bladder voiding difﬁculties, for urine output
monitoring or after lower urinary tract surgery and are typically usedon Group, School of Medicine, C
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. This is an open access article underfor between 1 and 14 days. Long-term catheterization may be used to
manage intractable urinary problems such as chronic urinary retention
or incontinence not treatable by other means, and here the aim is to
keep the catheter functioning and infection-free for as long as possible
but while medical opinion varies, and despite careful hygiene in han-
dling they usually need to be changed every 4–8 weeks [1]. Catheter-
associated urinary tract infection (CAUTI) is the commonest hospital-
acquired infection, accounting for 40% of all nosocomial infections and
over 100,000 admissions to hospital within the USA annually [2].
CAUTI rates have continued to rise in almost every care unit type [3].
The most common CAUTI pathogen is Escherichia coli, followed by
Proteus mirabilis [4]. Others, such as Klebsiella pneumoniae, Enterobacter
spp, enterococci and staphylococci are important but less common, and
Pseudomonas aeruginosa and Candida spp may be seen in longer-
catheterized patients, particularly after repeated courses of antibiotics.
Increasingly, strains of E. coli andK. pneumoniaeproduce extended spec-
trum beta-lactamases (ESBL), making them insusceptible to even the
newer cephalosporin antibiotics and presenting added therapeutic chal-
lenges. As in other devices, CAUTI pathogens are able to attach to the
catheter material and to develop bioﬁlms. CAUTI due to P. mirabilis isthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Schematic of a catheterized urinary bladder, showing the Foley catheter in place.
The catheter is inserted into the bladder through the urethra, and the balloon is then in-
ﬂated with water using a syringe attached to a secondary channel in the catheter. The
function of the balloon is to prevent the catheter from slipping out of the bladder. Urine
enters the bladder from the kidneys via the ureters, and drains into the eye-holes in the
catheter and then into a collecting bag.
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block the catheter lumen, causing obstruction and risking kidney infec-
tion and septicemia.
At least two approaches for prevention of biomaterial infection have
been used. One involves modiﬁcation of the biomaterial surface to
reduce bacterial attachment, a pre-requisite event in bioﬁlm develop-
ment. This is usually aimed at making the biomaterial surface hydro-
philic [6,7] but a class of weakly amphiphilic polymers that resist
bacterial attachment have also been identiﬁed [8,9]. The second ap-
proach has been to attach active biocides such as antibiotics to biomate-
rial surfaces, or to impregnate them into the biomaterial itself. One
example of the use of surface biocides is silver-processing using various
techniques [10]. However, these have been disappointing in clinical use
[11] and few “anti-bioﬁlm” urinary catheters have reached the market.
Urinary catheters containing nitrofurazone have been evaluated in a
large randomized controlled clinical trial alongside silver-processed
and plain catheters, and neither of these “antimicrobial” commercially
available catheters showed a clinically signiﬁcant reduction of infection
[12]. International guidelines now state that the evidence is not sufﬁ-
cient to support their use in short-term (b30 days) or long-term
(N30 days) users [13] and nitrofurazone catheters are now no longer
available. In general, antimicrobial coatings either are depleted rapidly
by urine ﬂow, or become obliterated by a host protein conditioning
ﬁlm. We have previously reported an antimicrobial neurosurgical cath-
eter produced by an impregnation process that has a long duration of
activity conﬁrmed by thousands of successful implants [14–17] and
the process has been adapted for use in dialysis [18]. Our previous re-
search on dialysis catheters, using a different antimicrobial combina-
tion, concentrated on in vitro assessment of antimicrobial activity and
included investigation of potential for inﬂammatory reaction in the
extremely sensitive peritoneal cavity. Here we report the evaluation of
duration of activity of a different antimicrobial combination, drug con-
centrations and their distribution in the catheter material as well as
their release characteristics, effect of processing on mechanical proper-
ties, particularly of the important retention balloon, and surface analysis
on a novel antimicrobial catheter intended for long-term urinary drain-
age, with enhanced antimicrobial spectrum and duration of activity. The
antimicrobials chosen, rifampicin, sparﬂoxacin and triclosan, were cho-
sen for their spectrum of activity against CAUTI pathogens (rifampicinand triclosan against staphylococci, sparﬂoxacin and triclosan against
E. coli, K. pneumoniae and P. mirabilis). The choice was also governed
by their physicochemical characteristics: solubility in chloroform and
ability to diffuse through the crosslinked silicone matrix.
2. Materials and methods
2.1. Impregnation process
The impregnation process (Fig. 2) was carried out as described pre-
viously [14]. The antimicrobials, rifampicin (Sigma-Aldrich, Poole, UK),
triclosan (Ciba Speciality Chemicals, Macclesﬁeld, UK) and sparﬂoxacin
(Sigma-Aldrich) were chosen for their activity against the target bacte-
ria (CAUTI pathogens) and their chemical compatibility with the im-
pregnation process. Brieﬂy, the antimicrobials were dissolved together
in chloroform (Fisher Scientiﬁc, Loughborough, UK) to give concentra-
tions w/v of 0.2% rifampicin, 1% triclosan and 1% sparﬂoxacin. Foley
catheters/segments (Coloplast, Peterborough, UK) or silicone test discs
1 mm × 6 mm (Goodfellow, Cambridge, UK) were immersed in the so-
lution for 1 h, duringwhich the silicone swelled to approximately twice
its volume. The catheters and discswere then removed and rinsed in ab-
solute ethanol (Fisher Scientiﬁc) to remove residual solvent and drug,
and allowed to dry overnight at room temperature in a current of air.
During evaporation of the solvent the catheters returned to their previ-
ous dimensions (Fig. 2), leaving the antimicrobials distributed evenly
throughout the silicone matrix. Separately, a series of silicone test
discs was produced containing the above antimicrobial concentrations
as single agents. The segments and discs were then packaged and ster-
ilized by autoclaving at 121 °C for 15 min. The sterilization process had
no signiﬁcant effect on the antimicrobial activity (data not shown).
2.2. Assay of drug content and drug release proﬁles
Total drug content was determined by extracting catheter segments
in chloroform which was then evaporated at room temperature. Drug
residues were re-dissolved in acetonitrile and HPLC analysis was per-
formed (Agilent 1090 HPLC, Agilent Technologies, Berkshire, UK) (Sup-
plementary Method 1). The total concentration of each drug extracted
from the catheter segments was calculated using peak areas from cali-
bration curves and the total drug content per catheter was calculated.
All experiments were carried out in triplicate. Calibration curves
showed good linearity, with correlation coefﬁcients (R2) for rifampicin,
triclosan and sparﬂoxacin of 0.9961, 0.9955 and 0.9997 respectively. To
establish drug release concentrations, antimicrobial catheter segments
were placed into HPLC grade water (pH 7) (Fisher Scientiﬁc) in a
37 °C incubator with constant agitation. Segments were transferred
daily or every 2–4 days into fresh water over a period of 28 days. After
concentration by liquid–liquid extraction using chloroform, eluates
were evaporated and drug residues were re-dissolved and analyzed by
HPLC. Drug release concentrations were determined from calibration
curves. All tests were carried out in triplicate. Calibration curve correla-
tion coefﬁcients (R2) for triclosan and sparﬂoxacin were 0.9998 and
0.9999.
2.3. Distribution of drugs in the polymer
The distribution of the antimicrobials at the catheter surface after
impregnation and after soaking in phosphate-buffered saline (PBS,
Oxoid, Basingstoke, UK) for 12weeks with weekly changes was studied
by time of ﬂight secondary ion mass spectrometry (ToF-SIMS) depth
proﬁling. Transmission electronmicroscopy, on samples prepared by fo-
cussed ion beammilling or ultramicrotomy, was used to determine the
distribution of the three drugs in the polymer matrix and to investigate
their particle size. Elemental analysis was performed for the presence of
nitrogen, ﬂuorine and chlorine, expected to be present in the antimicro-
bials but absent from the polymer (Supplementary Method 2).
Impregnation process
Fig. 2. Impregnation and elution of antimicrobials from catheter. Schematic depiction of the method used to produce antimicrobial catheters. Catheters were added to a solution of anti-
microbials and given time to allow the solvent to swell the catheter (1 h). Catheters were then removed from solution and allowed to dry overnight, whereupon they returned to their
original size.
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It is important that any post-manufacture processing does not dam-
age the biomaterial, and the inﬂatable retention balloon is an obvious
site of susceptibility for any deterioration in mechanical properties. In
addition, the catheter itself is subject to tensile force during insertion
and removal. Urinary catheters were used in the “as-received” state
from the manufacturers (controls) and following impregnation with
the antimicrobial agents as described. Half of the control and antimicro-
bial catheters were placed in simulated urine [19] which was replaced
weekly for up to 12 weeks to mimic drug elution in the body, while
the other half remained in anunchanged state.Mechanical performance
of catheter shafts was assessed using an Instron 5985 (Imetrum Ltd.,
Bristol, UK) with a 5 kN loadcell connected to a video extensometer.
Data were recorded using Bluehill 2 software. A specialized clamping
conﬁguration was devised to connect the catheter tubing to the Instron
as is shown in Fig. 6a. Catheters were clamped to expose a 5 cm length
along themid-section of the catheter and coatedmetal targets were ap-
plied 3 cmapart to allow for tracking by the video extensometer. A force
was applied at a rate of 100 mm/min as the apparatus recorded the
stress. The force applied was continued until either the apparatus
reached its maximum length limit or until catheter failure (breakage)
occurred. All tests were conducted at room temperature and in all
cases three replicates of each analysis were performed. From the resul-
tant relationship between the stress and strain, the load (N), ultimate
tensile strength (MPa), elongation at break (mm) and modulus (MPa)
determined at 280–320% elongation were calculated. Tests on catheter
balloons (Supplementary Table 1) were adapted from ASTM F623 99
[20] and BSEN1616: 1997 [21]. The control and antimicrobial balloons
were immersed in artiﬁcial urine [19] for 30 days at 37 °C. Balloon secu-
rity was tested by inserting the catheter tips, with balloon inﬂated,
through an inverted funnel and a 1 kgweight applied to pull the balloon
against the neck of the funnel. Failure consists of leakage or rupture of
the balloon and distortion so that the eye-holes of the catheter become
occluded. All control and impregnated balloons, before and after
soaking, passed the test. Balloon volume retention was tested by inﬂat-
ing themwith 10mL of 0.5 g/Lmethylene blue and placing on an absor-
bent white background (to detect dye leakage) for 30 days.2.5. Atomic force microscopy
An increase in surface roughness might facilitate mineral encrusta-
tion and could cause discomfort on catheter removal. Segments of con-
trol and impregnated catheters 1 cm longwere placed in PBS at 37 °C for
12 weeks to simulate drug elution over the period of catheter use, with
fresh solution replaced every week and a second identical set was left
unsoaked. Atomic force microscopy was used to determine surface
roughness (Rq value). All tests were performed in triplicate. Sections
(approx 2 × 2 mm) of catheter segments were mounted onto metal
stubs for analysis byAFM, andmeasurementswere conducted on aMul-
tiMode 8 AFM (Bruker) with a Nanoscope V controller operated in aPeakForce Quantitative NanoMechanics (QNM) mode in air using a sil-
icon nitride cantilever with a 0.1 N/m nominal spring constant. Two
5 μm × 5 μm surface area scans were performed on each catheter
segment.
2.6. Antimicrobial activity: serial plate transfer test
Test bacteria, chosen from isolates from patients with CAUTI in our
urology clinic, were one strain each of: Staphylococcus aureus (MRSA),
E. coli, P. mirabilis, K. pneumoniae, Staphylococcus saprophyticus and
Enterococcus faecalis. In addition, we tested a strain of ESBL— producing
E. coli. both S. aureus and S. saprophyticuswere susceptible to rifampicin;
E. faecalis had anMIC of rifampicin two logs higher, and the gram nega-
tive bacteriawere predictably resistant to this drug. Allwere susceptible
to triclosan except E. faecalis, which showed a low-level resistance. All
were susceptible to sparﬂoxacin except S. aureus and the ESBL strain
of E. coli. Minimum inhibitory concentrations (MICs) were determined
by agar incorporation or in the case of rifampicin, by Etest (AB Biodisk,
Solna, Sweden) and were shown in Supplementary Table 2. While a
simple zone plate is sufﬁcient to demonstrate antimicrobial activity, se-
rial transfer of the material to fresh plates will show how long the ma-
terial produces a zone of inhibition (Serial Plate Transfer Test, SPTT)
[14]. ISA agar (Oxoid) plates were seeded with the test bacteria (A490
0.6, ~1 × 107 cfu/mL) and impregnated silicone discs were placed in
triplicate on their surfaces and incubated overnight. Zones of inhibition
were measured with calipers and the discs were transferred to a fresh
seeded plate and incubated [22]. The process was repeated for
100 days or until no zones were produced (Fig. 5a). All tests were car-
ried out in triplicate.
2.7. Antimicrobial activity: time–kill study (tK100)
It is now recognized that,whenbacteria attach to a surface, their sus-
ceptibility to antimicrobials ismarkedly reduced [23] and it is important
to determine the ability of antimicrobial biomaterials to kill all, or most,
of attached bacteria within a reasonable time. This assay has been
termed the tK100 test, that is the time taken to kill 100%of attached bac-
teria. It is also recognized that when urinary catheters are contaminated
by bacteria in vivo, the bacteria usually encounter a biomaterial surface
that is overlaidwith a host-derived conditioningﬁlm [24]. Thiswas sim-
ulated by immersing the test discs and plain controls in ﬁlter-sterilized
human urine (pH 6.8) for 1 h at 37 °C. XPS was used to determine if a
conditioning ﬁlm had been deposited on the surface (Supplementary
Method 3). XPS conﬁrmed the presence of a protein conditioning ﬁlm
(Fig. 5b). The discswere then immersed in a suspension (approximately
1× 108 colony-formingunits/mL) of early log phase test bacteria and in-
cubated at 37 °C for 1 h for attachment to take place. After rinsing to re-
move unattached bacteria, triplicates of discs were placed in diluted
Tryptone Soya Broth (TSB, Oxoid) for up to 72 h, the dilution necessary
for survival of attached controls without planktonic multiplication
being found by experiment for each test isolate. For staphylococci 1%
was suitable but for others 0.1%–0.5% was best (data not shown). At
60 L.E. Fisher et al. / Journal of Controlled Release 202 (2015) 57–64intervals of 0, 24, 48 and 72 h, after rinsing and medium replacement
each day, triplicates of discs were removed and sonicated (50 Hz for
20 min) and surviving colonies plate counted.
2.8. Antimicrobial activity: serial bacterial challenge in ﬂow conditions
In order to simulate the ﬂow aspects of the catheters in use and to
ensure that any depletion of antimicrobial activity due to leaching was
detected, we used an established catheter challenge model [18]. This
consisted of a modular heating jacket into which the test catheters,
with balloon removed, were inserted and kept hydrated by a secondary
water jacket (Fig. 3a).
Tryptone Soya Broth was pumped through the catheters constantly
at 0.5 mL/min (representative of human urine production rate) until
the test ended. Each week, the test catheters (in triplicate) were inocu-
latedwith a suspension of ~1 × 105 cfu/mL of early log phase cultures of
S. aureus (MRSA), E. faecalis, E. coli (including the ESBL strain) or
P. mirabilis and the catheters clamped for 1 h to allow bacterial attach-
ment (Fig. 3b). Fresh plain unimpregnated control catheters were in-
cluded at each new inoculation. Flow was then restarted. Efﬂuent
samples from the distal end of the catheters were collected aseptically
each day and plated (200 μL per plate × 3) for colony counting. If no
growth was present after 7 days, a further inoculation was made, and
so on until either colonization occurred or 12 weekly challenges had
passed. Colonized control catheters were removed and renewed for
each challenge.
3. Results and discussion
3.1. Drug distribution and content of catheters and drug release proﬁles
The method of post-manufacture impregnation of Foley catheters
described here differs from others in that it allows post-extrusion intro-
duction of antimicrobials in a state that is not detectable by light or elec-
tronmicroscopy, and it allows the antimicrobials tomigrate through the
silicone matrix to replenish those lost from the catheter surface due to
ﬂuid ﬂow, thus giving an extended duration of activity. Processed cath-
eterswere found to contain a total of 0.49mg rifampicin (%RSD=12.3),
14.0 mg triclosan (%RSD = 5.1) and 13.25 mg sparﬂoxacin (%RSD =
11.8) equivalent to 0.006%, 0.17% and 0.16% w/w respectively (Fig. 4a).Fig. 3. Serial bacterial challenge in ﬂow conditions. (a) Schematic depiction of the experi-
mental setup for catheter challenge model experiments. (b) Example data of a standard
experiment. Bacteria were injected weekly and bacterial numbers were measured daily
at the sampling point. For each strain, measurements were taken for impregnated and un-
treated catheters.The release proﬁles for the drugs from the silicone catheter seg-
ments over a 28 day periodwere determined (Fig. 4b). Release of rifam-
picin from the catheter segments was not detected (limit of detection 1
μg/mL), probably because of the low initial total rifampicin content in
the catheters. At time-points over the 28 day release, the %RSD of triclo-
san varied between 5.9–33.4% and 11.1–44.3% for sparﬂoxacin, with the
higher RSD% being associated with concentrations of the drugs close to
the analytical limits of detection. After 28 days in water, 30% of the ini-
tial triclosan and 20% of the initial sparﬂoxacin had been released, sug-
gesting sufﬁcient drug left to diffuse over a prolonged time.
In ToF-SIMS analysis, the Si− secondary ion was characteristic of the
silicone substrate, the F− ion was characteristic for sparﬂoxacin and the
Cl−/37Cl− ions were characteristic for triclosan (Supplementary Fig. 1).
The CN− ion was representative for both sparﬂoxacin and rifampicin.
Sparﬂoxacin and triclosanwere shown to be evenly distributed laterally
but before soaking therewere some aggregates of both drugs at the sur-
face, due to residues accrued during drying, that disappeared after
soaking, though the drugs were still detected in the matrix (Fig. 4c).
ToF-SIMS depth proﬁles of the impregnated catheters showed an ele-
vated level of ions characteristic of drug compared with the untreated
catheter (Fig. 4d), and a heightened intensity at the surface of the cath-
eter. An even distribution of sparﬂoxacin and triclosan was observed
throughout the remainder of the catheter wall (Fig. 4e). The presence
of rifampicin could not be conﬁrmed by ToF-SIMS for the catheter con-
taining all three antimicrobials as representative ion for rifampicin
(CN−) was also observed in the ToF-SIMS spectra for sparﬂoxacin.
Therefore, to conﬁrm that impregnation of rifampicin occurred, a cath-
eter loaded only with this antimicrobial was assessed by ToF-SIMS
depth proﬁling. An elevated intensity of the CN− ionwas observed com-
pared to an untreated catheter, which continued into the wall of the
catheter, conﬁrming that rifampicin was successfully loaded into the
catheter using themethodology described. After a 12week elution, a re-
duction in secondary ions characteristic of the drugs was observed
throughout the catheter wall, suggesting that eluted drug is able to dif-
fuse evenly from the catheter matrix (Fig. 4f) as intended.
TEM was unable to detect the antimicrobials on any scale (data not
shown), and simulations indicated that the GIF Tridiem TEM would be
sensitive to localized drug concentrations of 10% or more by volume.
This would indicate an upper size limit on aggregates of antimicrobials
of 20 nm for the 200 nm-thick membrane analyzed in this study. This
implies that the drugs are present with particle sizes of b20 nm and
are probably in the form of a molecular dispersion rather than as gran-
ules as in the case when agents are added prior to extrusion.
3.2. Spectrum and duration of antimicrobial activity
The drug release proﬁles and antimicrobial activity show a long du-
ration of activity, considerably in excess of other experimental antimi-
crobial catheters. Cho et al. dipped their catheters in a mixture of
gentamicin and poly(ethylene-co-vinyl acetate but reported gentamicin
release for only 7 days [25] and reported 5 days in a rabbit model [26].
The same group reported inhibition zones for 10 days but did not report
a quantitative release proﬁle [27]. Raﬁenia et al. reported 12 days'
release from catheters dipped in a gentamicin–copolymer mix [28].
However, the extreme heterogeneity of antimicrobials, processing tech-
nology and test methods makes the published reports difﬁcult to com-
pare with each other and with our very different processing and
testing. Our duration data are also far in excess of those reported for
commercially available antimicrobial catheters [11,12] whose duration
of activity is a few days at the most. Our previous studies on these two
commercial catheters, silver-processed and nitrofural coated, showed
a duration of activity of ≤2 days in the SPTT, and both failed the ﬁrst
challenge in the ﬂow challenge test (data not shown), therefore validat-
ing the in vitro tests in respect of the clinical trial results.
In this SPTT study, discs impregnatedwith a combination of all three
drugs (Fig. 5a) showed continued inhibition of all except E. faecalis for
Fig. 4. (a) Table of the amount of each drug loaded into the antimicrobial catheter, as determined by HPLC. (b) Drug elution over 28 day course for triclosan ( ) and sparﬂoxacin ( ), as
determined by HPLC. (c) ToF-SIMS images of catheters untreated (left), after impregnation (middle) and after elution (right) for the total ion count, Cl− characteristic of triclosan and F−
characteristic of sparﬂoxacin. The scale bar= 100 μm. (d–f) ToF-SIMS depth proﬁles for (d) the untreated catheter, (e) impregnated catheter, and (f) catheter after elution. The area pro-
ﬁled was 100 Å–100 μm. Secondary ions tracked were Si− characteristic of silicone, Cl− characteristic of triclosan and F− characteristic of sparﬂoxacin. CN− was also tracked, which is
characteristic of both rifampicin and sparﬂoxacin. Ion intensity for CN from a catheter loaded with only rifampicin is shown in (e) as light green.
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cocci) and 36% (P. mirabilis) over this period. The inhibition zone for
E. faecalis fell steeply and declined to zero on Day 22. No resistance
was seen with any test bacterium in this assay. For the tK100 assay,
we applied a urinary protein conditioning ﬁlm. X-ray Photoelectron
Spectroscopy (XPS), used to verify the deposition of a conditioning
ﬁlm, showed an increase in carbon and nitrogen with a decrease in sil-
icon signal, indicating deposition of C + N rich material on the silicone
surface (Fig. 5b). No viable S. saprophyticus, S. aureus or K. pneumoniae
was found after 24 h. All E. coli were killed by 48 h and all E. faecalis
by 72 h. In the case of P. mirabilis, b25 cfu/mL remained at 72 h com-
pared to 105 cfu/mL from plain controls indicating a N99.9% reduction
(Fig. 5c and d). In the ﬂow challenge test, on each challenge, all the
control catheters became colonized by Day 1 and remained so until
removed (Table 1).
No colonies were observed for S. aureus and E. coli, including the
ESBL strain in efﬂuents for the 84-day duration of the challenge test.
Those challenged with P. mirabilis became colonized on Days 57, 78
and 85. The processed catheters failed to prevent colonization by
E. faecalis beyond Day 15. Repeat MIC determination on isolates from
failed catheters showed slight increases for P. mirabilis but still within
the susceptible range, and no change for E. faecalis, suggesting that in
each case failure to prevent colonization was not due to the develop-
ment of resistance. Resistance development was not seen after
prolonged exposure of test bacteria to the catheters in the Serial Plate
Transfer Test or in the Serial Challenge Flow Test. Concerns regardingresistance strains appearing as a result of use of antimicrobial catheters
are entirely justiﬁed and this is why we used these combinations of an-
timicrobials, which according to the Dual Drug Principle [29] would sig-
niﬁcantly reduce the likelihood of mutational resistance. Also, when
much higher inocula of P. mirabilis (~108 cfu/mL) have been exposed
to triclosan alone on agar surfaces they have shown evidence of muta-
tional resistance, as expected [30]. However, those mutants showing
MICs of 2 mg/L were still prevented from colonizing urinary catheters
in a laboratory model [30]. In most cases reduction of viable bacteria
was below the detectable levels, at least a ﬁve-log reduction (Table 1:
in vitro challenge, and Fig. 5c and d, tK100). Overall, the test catheters
were able to delay colonization by CAUTI pathogens between 7 and
12 weeks, with the exception of E. faecalis. The spectrum of activity
therefore extends to most of the CAUTI uropathogens, the exceptions
being P. aeruginosa, Candida and, except for the ﬁrst twoweeks, entero-
cocci. However, most CAUTI is caused by enterobacteria (E. coli,
K. pneumoniae, P. mirabilis) with a minority due to P. aeruginosa or
Candida in most studies [31].
Long-term urinary catheters have also been identiﬁed as reservoirs
for S. aureus includingMRSA [32] and our catheter also showed a strong
activity against these bacteria. As well as reducing CAUTI due to staph-
ylococci, the catheter promises to reduce spread of S. aureus and
MRSA, contributing to infection control measures. The results suggest
that this might similarly be the case for multi-resistant ESBL E. coli, re-
ducing the spread of these bacteria to the environment, to healthcare
workers and to other patients.
Fig. 5. Biological characterization of impregnated catheters. (a) Serial zone of inhibition analysis (Serial Plate Transfer Test) for impregnated silicone discs on an agar surface for E. faecalis
( ), K. pneumoniae ( ), P. mirabilis (●), S. aureus ( ), E. coli ( ), S. saprophyticus ( ), and ESBL E. coli ( ). (b) Atomic % of impregnated and untreated catheters with and without condi-
tioned ﬁlms, as determined by XPS. (c–d) tK100 assay on impregnated (solid line) and untreated (dotted line) catheters for (c) E. faecalis ( ), S. aureus ( ), S. saprophyticus ( ), and
(d) K. pneumoniae ( ), P. mirabilis (●), and E. coli ( ).
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balloon
The results show that neither the process itself nor the presence of
the antimicrobials affects themechanical properties of thematerial. Im-
pregnating the catheter and balloon with antimicrobial agents caused
no adverse effects to the mechanical performance (Fig. 6b, c).
Despite a load of 60–70 N applied at 100 mm/min, resulting in an
elongation of 377% (instrument limit) for all catheters, none was frac-
tured. There were no statistically signiﬁcant differences (2 tailed homo-
scedastic Student's t-test) between control and impregnated catheters
in their unused state with regard to load (p = 0.168), tensile strength
(p= 0.111), andmodulus (p= 0.054) or between control and impreg-
nated catheters after soaking in artiﬁcial urine for load (p=0.993), ten-
sile strength (p= 0.994) andmodulus (p= 0.381) (Fig. 6c). All control
and impregnated balloons, before and after soaking, passed the test. Noleakagewas seen from control or impregnated balloons, and in all cases
the balloons deﬂated fully at the end of the test (Supplementary
Table 1), an essential requirement in clinical use to allow free removal
of the catheter from the bladder. Impregnating the catheter and balloon
with antimicrobial agents therefore caused no adverse effects to theme-
chanical performance. The processing and impregnation did not change
the surface roughness of the catheters. There was no signiﬁcant differ-
ence (2 tailed homoscedastic Student's t-test) in Rq values between
control and impregnated catheters before soaking (p = 0.240), but
after soaking the impregnated catheters showed an increase in the
Rq value (9.57 nm ± 1.35 s.d. vs 22.72 nm ± 4.33 s.d., p =
1.628 × 10−15), presumably due to the release of antimicrobials during
soaking (Fig. 6d). This nm increase in surface roughness would be un-
likely to cause patient discomfort, or act to promote bacterial coloniza-
tion or mineral encrustation, though further testing of mineral
encrustation propensity would be required to exclude this possibility.
Table 1
Results of the serial ﬂow catheter challenge. During constant ﬂow, catheters
(in triplicate) were challenged weekly with a suspension of ~1 × 105 cfu/mL
of early log phase cultures of S. aureus (MRSA), E. faecalis, E. coli (including
the ESBL strain) or P. mirabilis and the catheters clamped for 1 h to allow bac-
terial attachment. After resumption of ﬂow, efﬂuents were plated daily for
quantitation. Challenges were repeated until colonization occurred or until
12 successive challenges had been administered. Control (plain) catheters
were renewed at each challenge. All control catheters showed colonization
within 24 h. Catheters withstood challenge with S. aureus, E. coli and ESBL
E. coli for at least 12 challenges (84 days), while the three challenged with
P. mirabilis became colonized after 57, 78 and 84 days respectively. Protection
against colonization by E. faecaliswas shortlived, lasting for 15 days.
Test bacterium Day of failure
Staphylococcus aureusMRSA N84
Enterococcus faecalis 15
Escherichia coli N84
Escherichia coli ESBL N84
Proteus mirabilis 57, 78, 84
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Currently available “antimicrobial” urinary catheters have been
shown not to be effective in laboratory and clinical studies, and there
is no catheter available for either short-term or long-term catheter
users, leaving them with the problem of recurring infection and ob-
struction leading to painful catheter changes. If the antimicrobialFig. 6.Mechanical characterization of impregnated catheters. (a) Image of the setup used to asse
untreated (right) catheters with the balloon inﬂated. (c) Table of themechanical measurement
terization of untreated and impregnated catheters before (left) and after (right) elution, show
were acquired from an area of 5 μm–5 μm.catheter were to prove to be effective in clinical use then a considerable
saving in hospital time and treatment and vastly improved quality of life
for patients could be achieved. The results suggest that the impregnated
cathetersmight reduce CAUTI in both short-term and long-termurinary
catheter use. Though this reduction is difﬁcult to quantify at this stage, it
is likely that, if CAUTI could be prevented or signiﬁcantly delayed in a
new catheter user, the concomitant reduction in antibiotic use might
also avoid progression to infection by Pseudomonas or Candida, and in
any casewould contribute considerably to the drive to reduce antibiotic
resistance.
Further studies on the antimicrobial catheter will include an evalua-
tion of its ability to reduce or prevent mineral encrustation, before a
Phase 1 study followed by a full Phase 2 clinical efﬁcacy trial.
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